Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition 2024

Singapore, May 3, 2024 – Axcynsis Therapeutics is proud and honoured to share that we were awarded the second place in the recent Pitch Competition co-hosted by Boston Chinese Investment Club, BCIC and Hong Kong Science and Technology Parks Corporation, HKSTP, on 27th April 2024! A total of 14 selected finalists, ranging from early-stage to mid-stage in pharmaceutical, medical device and diagnostics sectors, presented their transformative ideas to a distinguished panel of judges and an audience of industry leaders, investors, and media.

“It was our first time participating in this BCIC Pitch competition and we are really honoured to be awarded the second prize. We would like to extend our gratitude to BCIC and HKSTP to organise this event and for the chance to showcase our company and technology.”, says Dr. Zou Bin, Founder & CEO of Axcynsis Therapeutics. “Thank you to all the judges for the support and recognition. We hope that more organisations will also join us in this journey to develop the next First-in-class ADC!”

Our team in USA were also thrilled to be able to participate in the event on site at Boston!

Source2024 Biomedical Pitch Competition Winners – Boston Chinese Investment Club (


BCIC is a Massachusetts-registered non-profit organisation founded in 2010 with serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields between the US and China. Since 2022, the organisation has hosted annual biomedical pitch competitions, empowering startups to secure over $60 million in collective funding.


HKSTP was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 14,000 research professionals and over 1,700 technology companies from 27 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Through their R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues contribute in establishing I&T as a pillar of growth for Hong Kong.


Axcynsis Therapeutics stands at the forefront of innovation in antibody-drug conjugates (ADCs). Fuelled by a robust intellectual property portfolio, our pioneering approach seamlessly integrates advanced AxcynMAB™ antibody discovery, AxcynCYS™ site-specific conjugation, and a proprietary payload, AxcynDOT™, with a novel mechanism of action, positioning us as a key player in developing the Best-in-class to the First-in-class next generation ADCs. Since our inception 2 years ago, Axcynsis Therapeutics has established a portfolio with highly differentiated assets. The leading asset wiill achieve IND submission by end of 2024.


Axcynsis Therapeutics Media Contact:
Yun Xuan, Wong
+65 6550 2963